Novel targets NonExomics focuses on the dark genome and has identified over 250,000 new proteins across 1,365 human diseases, presenting a broad set of underexplored drug targets for diagnostics and therapeutics collaborations.

AI driven platform With AI-based algorithms analyzing population-scale patient data, there is a compelling value proposition for partnerships to accelerate target validation, biomarker discovery, and cross-disease therapeutic strategies.

Collaborative opportunities The company explicitly seeks collaborations across modalities including small molecules, antisense oligos, antibodies, and gene therapy, enabling multiple entry points for potential CDx/therapeutics partnerships.

Early stage readiness Recent platform launches and miniPROs initiatives demonstrate readiness to engage with industry players for co-development and joint ventures in challenging-to-target rare cancers and other diseases.

Growth and market fit With reported revenue in the low to mid single digits and a small team, NonExomics offers an agile, high-traction partner for early-stage collaborations that can scale leverageable insights into larger biotech ecosystems.